Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. kinpen

kINPen

Developing a high-innovative portable cold plasma device for efficient healing of chronic wounds in veterinary medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 kINPen project word cloud

Explore the words cloud of the kINPen project. It provides you a very rough idea of what is the project "kINPen" about.

time    anti    uv    pharmacological    innovative    network    ions    ca    forming    radiation    months    plasma    segments    feeling    antimicrobial    animal    neoplas    area    revolutionize    calculated    commercialization    stimulates    unpleasant    effect    stimulation    microorganism    opportunity    reachable    cold    vet    healing    950    first    led    regional    approximate    900    antiviral    reg    resistance    resistant    inflammatory    antibiotic    suppliers    presenting    rising    turnover    investment    medical    constitutes    18    surface    technologies    600    country    species    treatments    urgently    50    price    revenues    successfully    market    kinpen    radicals    chronic    costumers    return    electrical    farming    advantages    microorganisms    million    wound    obtaining    bacteria    laser    antifungal    pet    sales    110    100    generate    physiological    safe    organic    efficient    portable    farm    ultrasound    device    overconsumption    fungi    wellbeing    veterinary    electromagnetic    uses    accelerates    wounds    antibiotics    excited    equals    gas    share    sustainable    multidrug    electrons    health    treatment    infection    animals    manoeuvrable    ionized   

Project "kINPen" data sheet

The following table provides information about the project.

Coordinator		 NEOPLAS GMBH 

Organization address
address: WALTHER RATHENAU STRASSE 49A
city: GREIFSWALD
postcode: 17489
website: www.neoplas.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website https://www.neoplas.eu/en/veterinarymedicine.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEOPLAS GMBH DE (GREIFSWALD) coordinator 50˙000.00

Map

 Project objective

The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or LED, are less efficient, given their cost, unpleasant feeling, treatment-time or required area. Therefore, neoplas GmbH successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals. It stimulates and accelerates physiological wound healing and is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country. The production costs have been calculated with 5.900 €/ unit in the first 3 years and with a rising production the costs will be reduced to ca. 4.600 €/unit. The sales price is targeted with 8.900 €/unit and will allow a calculated return on investment in under 18 months.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KINPEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More